Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
June 5, 2006
- More than 90% of Consumers Aware of GE Drugs: Sawai
June 5, 2006
- Top 25 JPMA Member Companies Report Combined Growth in Sales, Profits
June 5, 2006
- Generics Account for 30% of Prescriptions in Dermatology
June 5, 2006
- Shionogi: Royalties Prop Up Profits Despite Lower Sales
May 29, 2006
- Industry Should Oppose Unreasonable Proposals: New FPMAJ President
May 29, 2006
- Mr T. Korekane Appointed President: Ono
May 29, 2006
- So-net M3 Starts Trial Run of "Doctors Blog"
May 29, 2006
- Santen: Ethical Drug Sales Up Domestically and Overseas
May 29, 2006
- STATISTICS
May 29, 2006
- Meiji Seika: Sales of Ethical Drugs Up 6.2% to \94,353 Mil.
May 29, 2006
- Terumo and Yakult Honsha Codevelop Irinotecan DDS
May 29, 2006
- Meiji Seika Announces New Midterm Management Plan
May 29, 2006
- Usefulness of MD Studies Stressed at Mass Spectrometry Conference
May 29, 2006
- Kaken: Sales of Generics Up 39.5%
May 29, 2006
- Korosho to Set Up New Clinical Study Search System
May 29, 2006
- Kyorin: Domestic Market Drives Growth in Sales
May 29, 2006
- R&D NEWS IN BRIEF
May 29, 2006
- SURVEY 2 articles
May 29, 2006
- Mochida: Epadel, Atelec Drive Growth in Sales, Profits
May 29, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…